Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors

Medical Oncology

Volumn 31, Issue 1, 2014, Pages

  Nishikawa, Masatomo ^a   Miyake, Hideaki ^a   Harada, Ken Ichi ^a   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

4E BP1; mTOR inhibitors; Prognosis; Radical nephrectomy; Renal cell carcinoma

Indexed keywords

BINDING PROTEIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHORYLATED 4E BINDING PROTEIN 1; PROTEIN KINASE B; PROTEIN P70; S6 KINASE; TEMSIROLIMUS; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EIF4EBP1 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PHOSPHOPROTEIN; RAPAMYCIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

AGED; ARTICLE; BONE METASTASIS; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY METASTASIS; MALE; NEPHRECTOMY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADICAL NEPHRECTOMY; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; KIDNEY NEOPLASMS; METABOLISM; METASTASIS; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; EVEROLIMUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEPHRECTOMY; PHOSPHOPROTEINS; PHOSPHORYLATION; PROGNOSIS; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84888784519     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0792-4     Document Type: Article

References (21)

1. Fasolo A, Sessa C. Targeting mTOR pathways in human malignancies. Curr Pharm Des. 2012;18(27):66-77.
2. Sheppard K, Kinross KM, Solomon B, Pearson RB, Phillips WA. Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog. 2012;17:69-95.
3. Husseinzadeh HD, Garcia JA. Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma. Curr Clin Pharmacol. 2011;6:214-21.
4. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449-56.
5. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-81. (Pubitemid 46849157)
6. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688-96.
7. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289-96. (Pubitemid 34032623)
8. Kurahashi T, Miyake H, Hara I, Fujisawa M. Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. J Urol. 2007;177:757-61. (Pubitemid 46054000)
9. Abou Youssif T, Fahmy MA, Koumakpayi IH, et al. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer. 2011;117:290-300.
10. Zhou X, Tan M, Stone Hawthorne V, et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res. 2004;10:6779-88. (Pubitemid 39383026)
11. Dai B, Kong YY, Ye DW, Ma CG, Zhou X, Yao XD. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int. 2012;104:1009-16.
12. Singer EA, Gupta GN, Marchalik D, Slinivasan R. Evolving therapeutic targets in renal cell carcinoma. Curr Opin Oncol. 2013;25:273-80.
13. Zhang Y, Zheng XF. mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle. 2012;11:594-603.
14. Ducker GS, Atreya CE, Simko JP, et al. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 2013. doi: 10.1038/onc.2013.92.
15. Yellen P, Saqcena M, Salloum D, et al. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle. 2011;10:3948-56.
16. Lee CK, Marschner IC, Simes RJ, et al. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin Cancer Res. 2012;18:3188-96.
17. Figlin RA, de Souza P, McDermott D, et al. Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer. 2009;115:3651-60.
18. Pal SK, Figlin RA. Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma. Target Oncol. 2011;6:5-16.
19. Armengol G, Rojo F, CastellvI J, et al. 4E-binding protein 1: a key molecular ''funnel factor'' in human cancer with clinical implications. Cancer Res. 2007;67:7551-5. (Pubitemid 47281345)
20. She QB, Halilovic E, Ye Q, et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell. 2010;18:39-51.
21. Aziz SA, Sznol JA, Adeniran A, et al. Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. BMC Clin Pathol. 2013;1(13):3.